Study of REM-422 in Patients With AML or Higher Risk MDS
Status:
RECRUITING
Trial end date:
2027-06-15
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML